eMedicine Specialties > Dermatology > Reactive & Inflammatory Dermatoses

Vesicular Palmoplantar Eczema

Author: Wingfield Rehmus, MD, MPH, Co-Director of Clinical Trials, Clinical Instructor, Department of Dermatology, Stanford University Medical Center
Contributor Information and Disclosures

Updated: Aug 30, 2007

Introduction

Background

Vesicular palmoplantar eczema is a term used to describe a group of diseases characterized by vesiculobullous eruption involving mainly the hands and feet. Clinical presentations vary from acute dermatitis to more chronic relapsing and remitting disease patterns.

Although considerable overlap exists in the various forms of vesicular palmoplantar eczema, the disease can be divided into 4 distinct categories: pompholyx, subacute or chronic relapsing vesiculosquamous eczema, chronic vesiculohyperkeratotic or hyperkeratotic eczema, and id reactions.

Pompholyx may be further subdivided into vesicular and bullous forms in which patients present with acute eruptions of blisters over their palms and soles. Chronic vesiculosquamous eczema, also called dyshidrotic eczema, was initially thought to be caused by abnormal function of the sweat glands. This association has since been disproved, but the term dyshidrotic eczema is still used. Patients with this variant present with vesicles involving the inner sides of the fingers. The chronic hyperkeratotic variety involves mainly the central palms, where it causes thickening and fissures. This category is notoriously the most difficult to treat. An id reaction refers to vesicular eruption of the hands, caused by a distal focus of infection, with fungal infections being the most common.

Despite the wide range of clinical presentations, all 4 types are histologically characterized by features of dermatitis, such as spongiosis and exocytosis.

Pathophysiology

Vesicular palmoplantar eczema is often thought to have an unidentified intrinsic cause. Although many etiologic factors are described, the underlying pathology is unknown. Similarly, though certain triggers have been associated with the development or worsening of symptoms, how these triggers cause flares has not been elucidated.

The disease results in histologic evidence of dermatitis, such as spongiosis, which is often accompanied by lymphocytic infiltrates.

Frequency

United States

The frequency in the United States is unknown.

International

The true incidence is unknown, but vesicular palmoplantar eczema is probably responsible for 5-20% of all cases of eczema of the hand.

Mortality/Morbidity

Patients with mild cases of pompholyx have an excellent prognosis. The more severe chronic hyperkeratotic variety often requires lifelong treatment and results in considerable disability.

Sex

The male-to-female ratio is 1:1.

Age

Pompholyx most commonly occurs in patients aged 20-40 years, but it may occur in individuals of any age. Onset in patients younger than 10 years is unusual. The frequency of recurrent episodes of pompholyx decreases after middle age, although this is not true of chronic vesicular and hyperkeratotic variants.

Clinical

History

The severity of symptoms varies, ranging from mild discomfort to acute severe episodes. Patients rarely require hospitalization.

  • Itching, burning, and prickling sensations of the palms and soles precede the eruption of vesicles.
  • Thereafter, small (1- to 2-mm) vesicles form, most commonly on the lateral sides of the fingers. In pompholyx, the central areas of the palms and soles may or may not be involved.
  • Large vesicles can develop on the palms and soles and may coalesce to form confluent bullae.
  • The lesions last for 2-3 weeks, after which spontaneous resolution generally occurs. Occasionally, large bullae may need to be aspirated. This phase is followed by desquamation.
  • Palmoplantar eczema typically recurs, and episodes are more frequent during the spring and summer than in the fall and winter.
  • The chronic hyperkeratotic variety results in severe itching accompanied by thickening and fissuring of the palm. This effect may decrease the mobility of the affected hand.

Physical

Clinical signs depend on the stage of disease. An absence of erythema is often an important clinical feature in the acute and chronic forms.

  • Acute episodes are characterized by a sudden onset of small, clear vesicles or bullae that are said to be sago-like or tapioca-like in appearance (see Media File 1).
    • Vesicles and/or bullae are accompanied by severe, occasionally painful pruritus.
    • Small vesicles may enlarge or become more confluent and present as large bullae (especially on the palms and soles).
    • Vesicles and bullae subsequently dry out and resolve, usually without rupturing.
    • In most individuals, desquamation occurs 2-3 weeks after the onset of vesicles and bullae.
    • In some patients, a milder recurrence follows the initial severe episode.
    • Secondary infections, such as impetigo, cellulitis, or lymphangitis, are possible in patients with recurrent hand eczema.
    • Secondary nail changes (eg, dystrophic nails, irregular transverse ridging, pitting, thickening, discoloration) can also occur.
  • Subacute vesicular eczema tends to have a chronic relapsing course with more vesiculation and more erythema in the acute phases than in later phases.
    • Residual erythema or some dryness or scaling occurs in the less-active phases.
    • Fissures are common and painful sequelae.
  • A form of microvesicular palmar eczema also occurs in association with dry nummular (discoid) eczema.
  • Hyperkeratotic palmar eczema is characterized by highly itchy, hyperkeratotic palms. Fissures in the folds of the hands and fingers are common and painful. Fissures can limit use of the hands.
    • Typically, chronic eczema affects the central area of the palm or the palmar aspect of the hands and fingers.
    • Only occasionally are vesicles visible on clinical examination, but spongiosis is found on histology.
  • When they occur on the hands, id reactions typically involve the lateral sides of the fingers. These reactions often resolve when the primary infection is treated.

Causes

The etiology of hand eczema is unknown, but most observers suggest that intrinsic changes in the skin are responsible for this condition. A recent study of an autosomal dominant form of pompholyx found a genetic linkage on chromosome 18. Whether other forms have a similar genetic linkage is not clear. However, several exogenous factors have been implicated in the causation or worsening of the disease.

  • Coexisting atopy is common in patients with palmoplantar eczema. This is by no means the only causal relationship because many patients have no history of atopy.
  • Emotional stress may also trigger episodes.
  • Seasonal changes seem to be directly related to relapses, as episodes are most common in the spring and summer months. Warm weather has been known to initiate episodes.
    • Although dysfunction of the sweat glands is no longer accepted as the cause of dyshidrotic eczema, increased sweating seems to exacerbate the condition.
    • Photosensitivity to ultraviolet A (UVA)-1 has been reported as an etiologic factor in a small subset of patients with eczema. Therefore, worsening of the disease in summer months may be due to the increase in exposure to sunlight. UVA therapy is a widely accepted form of treatment for palmoplantar eczema.
  • Sensitivity to certain metals, particularly nickel, has been linked to the condition.
  • Other exogenous factors include balsams and various allergens in general.
  • Drugs responsible for inducing episodes include oral contraceptive pills and aspirin. Palmoplantar eczema occurring after intravenous immunoglobulin therapy is reported.
  • Bacterial infections play a role in both causation and in secondarily infecting lesions. Fungal infections are most commonly implicated in id reactions.
  • Cigarette smoking may reduce the efficacy of topical therapy with psoralen and UVA (PUVA).

More on Vesicular Palmoplantar Eczema

Overview: Vesicular Palmoplantar Eczema
Differential Diagnoses & Workup: Vesicular Palmoplantar Eczema
Treatment & Medication: Vesicular Palmoplantar Eczema
Follow-up: Vesicular Palmoplantar Eczema
Multimedia: Vesicular Palmoplantar Eczema
References

References

  1. Behrens S, von Kobyletzki G, Gruss C, Reuther T, Altmeyer P, Kerscher M. PUVA-bath photochemotherapy (PUVA-soak therapy) of recalcitrant dermatoses of the palms and soles. Photodermatol Photoimmunol Photomed. Apr 1999;15(2):47-51. [Medline].

  2. Burton JL, Holden CA. Morphological types of hand eczema, pompholyx. Eczema, lichenification and prurigo. In: Champion RH, Wilkinson DS, Ebling FJG, eds. Rook, Wilkinson, Ebling Textbook of Dermatology. 6th ed. Blackwell Science: 1998:650-2.

  3. Chen JJ, Liang YH, Zhou FS, Yang S, Wang J, Wang PG, et al. The gene for a rare autosomal dominant form of pompholyx maps to chromosome 18q22.1-18q22.3. J Invest Dermatol. Feb 2006;126(2):300-4. [Medline].

  4. Douwes KE, Karrer S, Abels C, Landthaler M, Szeimies RM. Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema?. Photodermatol Photoimmunol Photomed. Feb 2000;16(1):25-9. [Medline].

  5. Edman B. Palmar eczema: a pathogenetic role for acetylsalicylic acid, contraceptives and smoking?. Acta Derm Venereol. 1988;68(5):402-7. [Medline].

  6. Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. Apr 1999;40(4):612-4. [Medline].

  7. Egawa K. Topical vitamin D3 derivatives in treating hyperkeratotic palmoplantar eczema: a report of five patients. J Dermatol. May 2005;32(5):381-6. [Medline].

  8. Kim YJ, Kim MY, Kim HO, Park YM. Dyshidrosiform bullous pemphigoid. Acta Derm Venereol. 2004;84(3):253-4. [Medline].

  9. Kimball A. Vesicular palmoplantar eczema. In: Fitzpatrick's Dermatology in General Medicine. 2003.

  10. Man I, Ibbotson SH, Ferguson J. Photoinduced pompholyx: a report of 5 cases. J Am Acad Dermatol. Jan 2004;50(1):55-60. [Medline].

  11. Odia S, Vocks E, Rakoski J, Ring J. Successful treatment of dyshidrotic hand eczema using tap water iontophoresis with pulsed direct current. Acta Derm Venereol. Nov 1996;76(6):472-4. [Medline].

  12. Ogden S, Clayton TH, Goodfield MJ. Recalcitrant hand pompholyx: variable response to etanercept. Clin Exp Dermatol. Jan 2006;31(1):145-6. [Medline].

  13. Petering H, Breuer C, Herbst R, Kapp A, Werfel T. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol. Jan 2004;50(1):68-72. [Medline].

  14. Pickenäcker A, Luger TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol. Mar 1998;134(3):378-9. [Medline].

  15. Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol. 1999;455:343-8. [Medline].

  16. Schmidt T, Abeck D, Boeck K, Mempel M, Ring J. UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. Acta Derm Venereol. Jul 1998;78(4):318-9. [Medline].

  17. Schnopp C, Remling R, Mohrenschlager M, Weigl L, Ring J, Abeck D. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol. Jan 2002;46(1):73-7. [Medline].

  18. Schurmeyer-Horst F, Luger TA, Bohm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology. 2007;214(1):99-100. [Medline].

  19. Sugimura C, Katsuura J, Moriue T, Matsuoka Y, Kubota Y. Dyshidrosiform pemphigoid: report of a case. J Dermatol. Jul 2003;30(7):525-9. [Medline].

  20. Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. Nov 2002;47(5):667-71. [Medline].

  21. Uyttendaele H, Obadiah J, Grossman M. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy. J Drugs Dermatol. Jun 2003;2(3):337-41. [Medline].

  22. Vocks E, Plotz SG, Ring J. The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema. Dermatology. 1999;198(3):265-9. [Medline].

  23. Wilkinson JD. Vesicular palmoplantar eczema. In: Freedberg IM, Elsen AZ, Wolff K, eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. McGraw-Hill; 1999:1489-94.

  24. Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. Jan 2002;16(1):40-2. [Medline].

Further Reading

Keywords

pompholyx, dyshidrotic eczema, vesicobullous dermatitis, dyshidrosis, subacute vesiculosquamous eczema, chronic relapsing vesiculosquamous eczema

Contributor Information and Disclosures

Author

Wingfield Rehmus, MD, MPH, Co-Director of Clinical Trials, Clinical Instructor, Department of Dermatology, Stanford University Medical Center
Wingfield Rehmus, MD, MPH is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Medical Editor

James J Nordlund, MD, Professor Emeritus, Department of Dermatology, University of Cincinnati College of Medicine
James J Nordlund, MD is a member of the following medical societies: American Academy of Dermatology, Sigma Xi, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: 3M Pharmaceutical Grant/research funds Other; Graceway Pharmaceuticals Grant/research funds Other

Managing Editor

Jeffrey J Miller, MD, Associate Professor, Department of Dermatology, Penn State University, Milton S Hershey Medical Center
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.